Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation

Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation.  This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease.  It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE).

Abcentra is developing a therapeutic solution for patients with residual risk of a cardiovascular event because of inflammation.  Our therapeutics in development target and block oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease.

Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline).  Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors.

Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai.  Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.


Chris Farina, MS, RAC
Prediman K. Shah, M.D.
Jan Nilsson, M.D., PhD
Ryan Abbott, M.D., J.D.

Board of Directors

Prediman K. Shah, M.D.
Jan Nilsson, M.D., PhD
Willem Mesdag

Strategic Advisers




Our Pipeline

Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.